Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $9.25 and traded as high as $13.52. Bayer Aktiengesellschaft shares last traded at $13.41, with a volume of 2,856,719 shares traded.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BAYRY. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The company’s 50 day moving average price is $11.48 and its 200-day moving average price is $9.25. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.